Company intelligence / Profile preview
Ningbo Newbay Medical Technology
Ningbo, Zhejiang, Chinanewbaypharma.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Ningbo Newbay Medical Technology is developing several oncology drug candidates acquired through global licensing deals. Its lead asset, GDC‑0570/NB004—a pan-PIM kinase inhibitor—has completed early clinical safety/pharmacokinetic studies with data presented at AACR 2024. The company also holds rights to an EP4 antagonist and a c-KIT inhibitor, with additional preclinical work ongoing around PARP‑1 inhibitors. No late-stage or pivotal trial results have been reported publicly as of June 2025.
- Therapeutic areas
- Oncology
- Modalities
- Small molecule
- Industry
- Biotech
02
Drug pipeline
3 assets2 more assets in the full pipeline.
03
Partnerships
Beyond the preview
Go deeper on Ningbo Newbay Medical Technology.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Ningbo Newbay Medical Technology.